--Shares Begin Trading Over-the-Counter Under Symbol ‘TRGM’--
LOS ANGELES--(BUSINESS WIRE)-- Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today announced that effective today, its common shares will be trading over-the-counter under the symbol “TRGM” on OTC Market Group’s OTCQB market and the Over-the-Counter Bulletin Board (OTCBB). The company's publicly traded status follows FINRA's approval of its 15c2-11 filing.
“We are very excited to begin the next phase of the evolution of our company,” said William Shell, M.D., chief executive officer of Targeted Medical Pharma. “With medical foods gaining wider acceptance among physicians and patients, we believe the company is positioned to enjoy further growth, as we increase marketing efforts for our nine proprietary medical food products and focus on the development of new products that address large patient populations.”
Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc., is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, and sleep and cognitive disorders. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medications and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.
Investor Contacts:
PondelWilkinson
Roger Pondel | Matt Sheldon
investors@tmedpharma.com
(310) 279-5975
or
Media Contacts:
George Medici | gmedici@pondel.com
Ron Neal | rneal@pondel.com
(310) 279-5980
Source: Targeted Medical Pharma, Inc.